Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors

Glioblastoma is the most prevalent and aggressive brain cancer. With a median overall survival of ~15–20 months under standard therapy, novel treatment approaches are desperately needed. A recent phase II clinical trial with a personalized immunotherapy based on tumor lysate-charged dendritic cell (...

Descripción completa

Detalles Bibliográficos
Autores principales: Erhart, Friedrich, Hackl, Matthias, Hahne, Hannes, Buchroithner, Johanna, Meng, Chen, Klingenbrunner, Simone, Reitermaier, René, Fischhuber, Katrin, Skalicky, Susanna, Berger, Walter, Spiegl-Kreinecker, Sabine, Lötsch, Daniela, Ricken, Gerda, Kuster, Bernhard, Wöhrer, Adelheid, Widhalm, Georg, Hainfellner, Johannes, Felzmann, Thomas, Dohnal, Alexander M., Marosi, Christine, Visus, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965118/
https://www.ncbi.nlm.nih.gov/pubmed/31969991
http://dx.doi.org/10.1038/s41541-019-0149-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965118/
https://www.ncbi.nlm.nih.gov/pubmed/31969991
http://dx.doi.org/10.1038/s41541-019-0149-x

Ejemplares similares